One-year access to more than 500 world journals available in the system
-
http://medilib.ir
- Duration of Time : 365 Day
Price : 300$- Special Price : 100$
Identifying patients with type 2 diabetes who might benefit from insulin pump therapy: Literature review, clinical opportunities, potential benefits and challenges
Preethika Ekanayake MD, Steven Edelman MD,
doi : 10.1111/dom.15059
The global prevalence and increasing incidence rates of type 2 diabetes (T2D) have rippling effects on healthcare costs and diminishing quality of life. Despite advances in technology, continuous subcutaneous insulin infusion (CSII), or insulin pump therapy, is rarely being recommended by healthcare professionals and is underutilized in T2D management.
Use of insulin pumps and closed-loop systems among people living with diabetes: A narrative review of clinical and cost-effectiveness to enable access to technology and meet the needs of payers
Johan Jendle PhD, Yves Reznik PhD,
doi : 10.1111/dom.15087
The use of continuous subcutaneous insulin infusion (CSII) via insulin pumps is today considered standard of care for type 1 diabetes (T1D). Closed-loop systems combining continuous glucose monitoring with automated algorithm-driven insulin delivery have been shown to be safe and efficacious in randomized controlled trials and real-life studies in both paediatric and adult participants with T1D.
COVID-19 associated ketosis and diabetic ketoacidosis: A rapid review
Tharun T. Alamuri BS, Sandhya Mahesh, Kevin Dell'Aquila BS, Taylor Jan Leong BS, Rebecca Jennings BS, Tim Q. Duong PhD,
doi : 10.1111/dom.15036
SARS-CoV-2 infection could disrupt the endocrine system directly or indirectly, which could result in endocrine dysfunction and glycaemic dysregulation, triggering transient or persistent diabetes mellitus. The literature on the complex relationship between COVID-19 and endocrine dysfunctions is still evolving and remains incompletely understood. Thus, we conducted a review on all literature to date involving COVID-19 associated ketosis or diabetic ketoacidosis (DKA).
Efficacy and safety of bexagliflozin in patients with type 2 diabetes mellitus: A systematic review and meta-analysis
Eric Pasqualotto, Janine Midori Figueiredo Watanabe, Douglas Mesadri Gewehr, Raphaela da Silva Maintinguer, Simone van de Sande-Lee MD, Gustavo Neves de Araujo MD, Fidel Silveira Leal MD, Carlos Eduardo Andrade Pinheiro MD,
doi : 10.1111/dom.15051
To assess the efficacy of bexagliflozin in reducing glycated haemoglobin (HbA1c) and the occurrence of side effects in patients with type 2 diabetes (T2DM).
Allometric body shape indices, type 2 diabetes and kidney function: A two-sample Mendelian randomization study
Alisa D. Kjaergaard PhD, Jesse Krakauer MD, Nir Krakauer PhD, Alexander Teumer PhD, Thomas W. Winkler PhD, Christina Ellervik DMSc,
doi : 10.1111/dom.15037
To examine the association between body mass index (BMI)-independent allometric body shape indices and kidney function.
Clinical characteristics, treatment patterns, and persistence in individuals with type 2 diabetes initiating a glucagon-like peptide-1 receptor agonist: A retrospective analysis of the Diabetes Prospective Follow-Up Registry
Heike Jung MD, Sascha R. Tittel MSc, Nanette C. Schloot MD, Elke Heitmann PhD, Thorsten Otto MSc, Jeremie Lebrec PhD, Marianne Pavel MD, Stefanie Lanzinger PhD,
doi : 10.1111/dom.15038
To describe clinical characteristics, treatment patterns and glucagon-like peptide-1 receptor agonist (GLP-1 RA) persistence in individuals with type 2 diabetes (T2D) initiating their first GLP-1 RA.
Identification of predictive factors of diabetic ketoacidosis in type 1 diabetes using a subgroup discovery algorithm
Angela Ibald-Mulli PhD, Jochen Seufert MD, Julia M. Grimsmann PhD, Markus Laimer MD, Peter Bramlage MD, Alexandre Civet, Margot Blanchon, Simon Gosset, Alexandre Templier, W. Dieter Paar MD, Fang Liz Zhou MD, Stefanie Lanzinger PhD,
doi : 10.1111/dom.15039
To identify predictive factors for diabetic ketoacidosis (DKA) by retrospective analysis of registry data and the use of a subgroup discovery algorithm.
Estimating the value of sodium-glucose cotransporter-2 inhibitors within the context of contemporary guidelines and the totality of evidence
Phil McEwan PhD, Volker Foos MSc, Becky Martin MSc, Jieling Chen PhD, Marc Evans MB,
doi : 10.1111/dom.15040
To comprehensively estimate the cost-effectiveness of sodium glucose cotransporter-2 (SGLT2) inhibitor usage in the management of type 2 diabetes mellitus (T2DM) at established clinical review points, incorporating the totality of proven health benefits.
Efficacy and safety of empagliflozin in combination with insulin in Chinese patients with type 2 diabetes and insufficient glycaemic control: A phase III, randomized, double-blind, placebo-controlled, parallel study
Linong Ji MD, Yibin Lu MD, Qifu Li MD, Liujun Fu MS, Yong Luo MS, Tao Lei MD, Ling Li MD, Shandong Ye MD, Bimin Shi MD, Xiyan Li MS, Thomas Meinicke MD,Â
doi : 10.1111/dom.15041
To evaluate the efficacy and safety of empagliflozin in combination with insulin ± oral antidiabetic drugs (OADs) over 24 weeks, in Chinese patients with type 2 diabetes (T2D) who had insufficient glycaemic control.
Effect of gastric distension with concurrent small intestinal saline or glucose infusion on incretin hormone secretion in healthy individuals: A randomized, controlled, crossover study
Ryan J. Jalleh MBBS, Laurence G. Trahair PhD, Tongzhi Wu PhD, Scott Standfield BSc, Christine Feinle-Bisset PhD, Christopher K. Rayner PhD, Michael Horowitz DSc, Karen L. Jones PhD,
doi : 10.1111/dom.15042
To evaluate the effect of gastric distension, induced using a gastric ‘barostat’, on the secretion of glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide-1 (GLP-1) in the presence and absence of small intestinal nutrients in healthy individuals.
Once-weekly semaglutide use in patients with type 2 diabetes: Results from the SURE France multicentre, prospective, observational study
Kamel Mohammedi MD, Narimene Belhatem MD, Tina Landsvig Berentzen PhD, Andrei-Mircea Catarig PhD, Louis Potier MD,
doi : 10.1111/dom.15045
Real-world data are required to support glucagon-like peptide-1 receptor agonist use in type 2 diabetes (T2D). SURE France assessed once-weekly semaglutide in adults with T2D in real-world clinical practice.
Efficacy and safety of enavogliflozin, a novel SGLT2 inhibitor, in Korean people with type 2 diabetes: A 24-week, multicentre, randomized, double-blind, placebo-controlled, phase III trial
Soo Heon Kwak MD, Kyung Ah Han MD, Kyung-Soo Kim MD, Jae Myung Yu MD, EunSook Kim MD, Jong Chul Won MD, Jun Goo Kang MD, Choon Hee Chung MD, Seungjoon Oh MD, Sung Hee Choi MD, Kyu Chang Won MD, Sin Gon Kim MD, Seung Ah Cho PhD, Bo Young Cho MS, Kyong Soo Park MD,Â
doi : 10.1111/dom.15046
To evaluate the efficacy and safety of a novel sodium-glucose cotransporter 2 inhibitor, enavogliflozin 0.3Â mg monotherapy, in Korean people with type 2 diabetes mellitus (T2DM) inadequately controlled with diet and exercise.
Sotagliflozin, a dual sodium-glucose co-transporter-1 and sodium-glucose co-transporter-2 inhibitor, reduces the risk of cardiovascular and kidney disease, as assessed by the Steno T1 Risk Engine in adults with type 1 diabetes
Elisabeth B. Stougaard MD, Peter Rossing DMSc, Dorte Vistisen PhD, Phillip Banks MS, Manon Girard MSc, Michael J. Davies PhD, Frederik Persson DMSc,Â
doi : 10.1111/dom.15047
Sotagliflozin (SOTA) as adjunct to insulin therapy improves glycemic control, reduces body weight and blood pressure, and increases time in range in adults with type 1 diabetes (T1D). SOTA demonstrated CV and kidney benefits in high-risk adults with type 2 diabetes.
Inverse association between glucose variability and body fat in type 2 diabetes with impaired endogenous insulin secretion assessed using continuous glucose monitoring: A prospective observational study
Aika Miya MD, Akinobu Nakamura MD, Yuka Suzuki MD, Hiroshi Nomoto MD, Hiraku Kameda MD, Kyu Yong Cho MD, Yoichi M. Ito PhD, So Nagai MD, Hideaki Miyoshi MD, Tatsuya Atsumi MD,Â
doi : 10.1111/dom.15049
To evaluate the contribution of body fat mass and serum adiponectin concentration to glucose variability (GV) stability in people with type 2 diabetes with impaired versus preserved endogenous insulin secretion.
HbA1c trajectories over 3 years in people with type 2 diabetes starting second-line glucose-lowering therapy: The prospective global DISCOVER study
Brenda Bongaerts PhD, Oliver Kuss PhD, Fabrice Bonnet MD, Hungta Chen PhD, Andrew Cooper PhD, Peter Fenici MD, Marilia B. Gomes MD, Niklas Hammar PhD, Linong Ji MD, Kamlesh Khunti MD, Jesús Medina PhD, Antonio Nicolucci MD, Marina V. Shestakova MD, Hirotaka Watada MD, Wolfgang Rathmann MD,Â
doi : 10.1111/dom.15050
To identify distinct HbA1c trajectories in people with type 2 diabetes (T2D) starting second-line glucose-lowering therapy.
Association between walking pace and incident type 2 diabetes by adiposity level: A prospective cohort study from the UK Biobank
Jirapitcha Boonpor MSc, Solange Parra-Soto MSc, Jasunella Gore MSc, Atefeh Talebi PhD, Nathan Lynskey MSc, Andrea Raisi MSc, Paul Welsh PhD, Naveed Sattar MD, Jill P. Pell MD, Jason M. R. Gill PhD, Stuart R. Gray PhD, Frederick K. Ho PhD, Carlos A. Celis-Morales PhD,
doi : 10.1111/dom.15053
To investigate the combined association of adiposity and walking pace with incident type 2 diabetes.
High cereal fibre but not total fibre is associated with a lower risk of type 2 diabetes: Evidence from the Melbourne Collaborative Cohort Study
Robel Hussen Kabthymer, Md Nazmul Karim, Allison M Hodge, Barbora de Courten MD,Â
doi : 10.1111/dom.15054
To assess the associations of total dietary fibre and fibre from different food sources (ie, cereal, fruit and vegetables) with the risk of diabetes.
Vascular and metabolic effects of ipragliflozin versus sitagliptin (IVS) in type 2 diabetes treated with sulphonylurea and metformin: IVS study
Seon Mee Kang MD, Han Mi Yun BS, Minji Sohn PhD, Soo Lim MD,Â
doi : 10.1111/dom.15056
In patients with type 2 diabetes who were inadequately controlled with metformin and sulphonylurea, we compared the glucose-lowering efficacy, cardiometabolic parameters and safety of two drugs, ipragliflozin, a sodium-glucose cotransporter-2 inhibitor, and sitagliptin, a dipeptidyl peptidase-4 inhibitor.
Effects of oral semaglutide on cardiovascular outcomes in individuals with type 2 diabetes and established atherosclerotic cardiovascular disease and/or chronic kidney disease: Design and baseline characteristics of SOUL, a randomized trial
Darren K. McGuire MD, Rodica P. Busui MD, John Deanfield MD, Silvio E. Inzucchi MD, Johannes F. E. Mann MD, Nikolaus Marx MD, Sharon L. Mulvagh MD, Neil Poulter FRCP, Mads D. M. Engelmann MD, G. Kees Hovingh MD, Maria Sejersten Ripa MD, Mette Gislum MSc, Kirstine Brown-Frandsen MD, John B. Buse MD,Â
doi : 10.1111/dom.15058
To describe the design of the SOUL trial (Semaglutide cardiOvascular oUtcomes triaL) and the baseline clinical data of its participants.
Glycaemic control and sepsis risk in adults with type 1 diabetes
Anca Balintescu MD, Marcus Lind MD, Mikael Andersson Franko PhD, Anders Oldner MD, Maria Cronhjort MD, Björn Eliasson MD, Christer Svensen MD, Johan MÃ¥rtensson MD,Â
doi : 10.1111/dom.15060
Clinical features of generalized lipodystrophy in Turkey: A cohort analysis
Ilgin Yildirim Simsir MD, Beyhan Tuysuz MD, Mehmet Nuri Ozbek MD, Seher Tanrikulu MD, Merve Celik Guler MD, Asuman Nur Karhan MD, Yasemin Denkboy Ongen MD, Nilay Gunes MD, Utku Erdem Soyaltin MD, Canan Altay MD, Banu Nur MD, Servan Ozalkak MD, Ozlem Akgun Dogan MD, Fatma Dursun MD, Zafer Pekkolay MD, Mehmet Ali Eren MD, Yusuf Usta MD, Secil Ozisik MD, Basak Ozgen Saydam MD, Suleyman Cem Adiyaman MD, Mehmet Cagri Unal MD, Gokcen Gungor Semiz MD, Ihsan Turan MD, Erdal Eren MD, Hulya Kayserili MD, Isabelle Jeru PhD, Corinne Vigouroux MD, Tahir Atik MD, Huseyin Onay MD, Samim Ozen MD, Elif Arioglu Oral MD, Baris Akinci MD,Â
doi : 10.1111/dom.15061
To describe the Turkish generalized lipodystrophy (GL) cohort with the frequency of each complication and the death rate during the period of the follow-up.
Ultra rapid lispro showed greater reduction in postprandial glucose versus Humalog in children, adolescents and adults with type 1 diabetes mellitus
Ronnie Aronson MD, Torben Biester MD, Jennifer Leohr PhD, Robyn Pollom ANP, Helle Linnebjerg PhD, Elizabeth Smith LaBell BS, Qianyi Zhang PhD, David E. Coutant PhD, Thomas Danne MD,Â
doi : 10.1111/dom.15063
This study compared the pharmacokinetics, glucodynamics and tolerability following single subcutaneous doses of ultra rapid lispro (URLi) versus Humalog in children (6-11 years), adolescents (12-17 years) and adults (18-64 years) with type 1 diabetes mellitus (T1D).
A randomized Phase I study of the safety, tolerability, pharmacokinetics and pharmacodynamics of BI 456906, a dual glucagon receptor/glucagon-like peptide-1 receptor agonist, in healthy Japanese men with overweight/obesity
Rie Yazawa MD, Masahiro Ishida MA, Yesilda Balavarca PhD, Anita M. Hennige MD,Â
doi : 10.1111/dom.15064
To report a Phase I study of subcutaneous glucagon receptor (GCGR)/glucagon-like peptide-1 receptor (GLP-1R) dual agonist BI 456906 versus placebo in healthy Japanese men with overweight/obesity.
Astaxanthin, a natural antioxidant, lowers cholesterol and markers of cardiovascular risk in individuals with prediabetes and dyslipidaemia
Theodore P. Ciaraldi PhD, Schafer C. Boeder MD, Sunder R. Mudaliar MD, Erin R. Giovannetti NP, Robert R. Henry MD, Jeremy H. Pettus MD,Â
doi : 10.1111/dom.15070
To determine the effects of astaxanthin treatment on lipids, cardiovascular disease (CVD) markers, glucose tolerance, insulin action and inflammation in individuals with prediabetes and dyslipidaemia.
Assessment of circulating insulin using liquid chromatography-mass spectrometry during insulin glargine treatment in type 2 diabetes: Implications for estimating insulin sensitivity and β-cell function
Jesse C. Seegmiller, David J. Schmit, Valerie L. Arends, Michael W. Steffes, Steven E. Kahn MB ChB, Naji Younes PhD, the GRADE Research Group ,
doi : 10.1111/dom.15072
To determine the potential impact of the cross-reactivity of insulin glargine U-100 and its metabolites on insulin sensitivity and β-cell measures in people with type 2 diabetes.
iGlarLixi provides a higher derived time-in-range versus insulin glargine 100 U/mL or lixisenatide in Asian Pacific people with type 2 diabetes: A post hoc analysis
Xiaohui Guo MD, Wenying Yang MD, Junqing Zhang MD, Xiaolin Dong MD, Ming Liu MD, Shenghong Gu MCM, Felipe Lauand MD, Lingyu Li MS, Qiong Huang MS, Lei Kang MD, Elisabeth Souhami MD,
doi : 10.1111/dom.15074
To evaluate the efficacy of iGlarLixi in the Asian Pacific (AP) population with type 2 diabetes (T2D) using derived time-in-ranges calculated from seven-point self-measured blood glucose.
A UK nationwide study of adults admitted to hospital with diabetic ketoacidosis or hyperosmolar hyperglycaemic state and COVID-19
Benjamin C. T. Field PhD, Yue Ruan PhD, Kinga A. Várnai MSc, Jim Davies DPhil, Robert E. J. Ryder MD, Rajiv Gandhi MD, Sophie Harris PhD, Dinesh Nagi PhD, Dipesh Patel PhD, Punith Kempegowda PhD, Sarah H. Wild PhD, Emma G. Wilmot PhD, Kamlesh Khunti PhD, Rustam Rea MD, Parth Narendran PhD, on behalf of the ABCD COVID-19 Audit Group ,Â
doi : 10.1111/dom.15076
To investigate characteristics of people hospitalized with coronavirus-disease-2019 (COVID-19) and diabetic ketoacidosis (DKA) or hyperosmolar hyperglycaemic state (HHS), and to identify risk factors for mortality and intensive care admission.
Ketone monoester increases circulating levels of LEAP2 and decreases appetite in healthy men
Stephanie Kjærulff Holm PhD student, Esben Thyssen Vestergaard PhD, Natasa Brkovic Zubanovic PhD student, Sarah Byberg PhD, Christoffer Clemmensen PhD, Birgitte Holst PhD, Henrik Holm Thomsen PhD,Â
doi : 10.1111/dom.15044
Antidiabetes medication initiation trends in US adults with cirrhosis and type 2 diabetes: A nationwide study
Tracey G. Simon MD, Deborah J. Wexler MD, Sebastian Schneeweiss MD, Elisabetta Patorno MD,Â
doi : 10.1111/dom.15052
Advanced hybrid closed loop system use in elderly with type 1 diabetes: Effectiveness and safety in a prospective, observational, 1-year follow-up real-world study
Basilio Pintaudi MD, Ilaria Gironi MSc, Elena Meneghini MD, Matteo Conti MD, Chiara Guidoni MD, Giacoma Di Vieste MD, Anna Grattieri MD, Olga Disoteo MD, Elena Mion MD, Federico Bertuzzi MD,Â
doi : 10.1111/dom.15055
Cardiovascular and kidney outcomes with canagliflozin according to type 2 diabetes treatment targets at baseline: Data from the CANVAS programme and CREDENCE
Michael A. Tsoukas MD, Vincent Woo MD, Sheldon W. Tobe MD, April Slee PhD, Wally Rapattoni BPharm, Fernando G. Ang MD, Jochen Seufert MD, Brendon L. Neuen MBBS, Clare Arnott MBBS, Kenneth W. Mahaffey MD, David C. Wheeler MD,Â
doi : 10.1111/dom.15057
Effects of canagliflozin on cardiovascular and kidney events in patients with chronic kidney disease with and without peripheral arterial disease: Integrated analysis from the CANVAS Program and CREDENCE trial
Tae Won Yi MD, Michelle M.Y. Wong MD, Brendon L. Neuen MD, Clare Arnott MD, Paul Poirier MD, Jochen Seufert PhD, April Slee PhD, Wally Rapattoni MSc, Fernando G. Ang PhD, David C. Wheeler MD, Kenneth W. Mahaffey MD, Vlado Perkovic MD, Adeera Levin MD,Â
doi : 10.1111/dom.15065
